Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tadalafil

- PMLiVE

Johnson & Johnson to acquire Alios BioPharma for $1.75bn

Will gain access to the biopharma's portfolio of viral infection candidates

- PMLiVE

Janssen, AZ and Roche at ESMO

Companies present promising data on new cancer drugs

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

Janssen ‘extremely disappointed’ by NICE’s Olysio guidance

Hepatitis C drug only recommended use for one out of three licenced indications

- PMLiVE

Germany’s IQWiG denies Astellas’ incontinence drug

But Janssen receives recommendation for hepatitis C treatment Olysio

- PMLiVE

Illumina partners with pharma majors on cancer diagnostic

Will work with AstraZeneca, Janssen and Sanofi to develop gene sequencing tool

- PMLiVE

NICE backs Gilead’s Sovaldi in hepatitis C

But health watchdog denies earlier use of Janssen’s Zytiga

- PMLiVE

Janssen looks to NASCAR for atrial fibrillation awareness

Company's MyAFibStory.com 400 kicks off the NASCAR Sprint Cup series

- PMLiVE

Janssen launches online mental health video series

Healthy Minds will focus on brain disorder research and treatment

- PMLiVE

J&J’s Imbruvica wins new cancer indication

FDA backs drug’s use in chronic lymphocytic leukaemia patients with genetic mutation

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

- PMLiVE

Olysio leads charge at J&J but competition is on the way

CEO Gorsky warns that Gilead’s Sovaldi will impact sales of hepatitis C drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links